NCT07282600招募中3 期
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,035
- 试验地点
- 322
- 主要终点
- Percent Change from Baseline in Body Weight
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have type 2 diabetes
- •Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
- •Have a BMI ≥ 27 kg/m2
- •Have a stable body weight (<5% body weight change) for 90 days prior to screening
排除标准
- •Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
- •Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- •Have type 1 diabetes
- •Have taken any of the following antihyperglycemic medications within 90 days before screening:
- •amylin analogs
- •glucagon-like peptide-1 (GLP-1) receptor agonists
- •glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
- •Have had within 90 days prior to screening:
- •heart attack
- •coronary artery revascularization
- •unstable angina, or
- •hospitalization due to congestive heart failure
- •Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- •Have taken medications or alternative remedies intended for weight loss within 90 days of screening
研究组 & 干预措施
Eloralintide Dose 2
Experimental
Participants will receive eloralintide SC
干预措施: Eloralintide (Drug)
Placebo
Placebo Comparator
Participants will receive placebo SC
干预措施: Placebo (Drug)
Eloralintide Dose 3
Experimental
Participants will receive eloralintide SC
干预措施: Eloralintide (Drug)
Eloralintide Dose 1
Experimental
Participants will receive eloralintide subcutaneously (SC)
干预措施: Eloralintide (Drug)
Eloralintide Dose 4
Experimental
Participants will receive eloralintide SC
干预措施: Eloralintide (Drug)
结局指标
主要结局
Percent Change from Baseline in Body Weight
时间窗: Baseline, Week 64
Percent Change from Baseline in Body Weight
时间窗: Baseline, Week 64
次要结局
- Change in Medication Use(Baseline through Week 64)
- PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)(Baseline through Week 64)
- Percent Change from Baseline in Total Body Fat Mass(Baseline, Week 64)
- Change from Baseline in Waist Circumference(Baseline, Week 64)
- Change from Baseline in Hemoglobin A1c (HbA1c)(Baseline, Week 64)
- Percent Change in Baseline in Triglycerides(Baseline, Week 64)
- Change from Baseline in Systolic Blood Pressure(Baseline, Week 64)
- Change from Baseline in Body Mass Index (BMI)(Baseline, Week 64)
- Percent Change from Baseline in Total Body Fat Mass(Baseline, Week 64)
- Change from Baseline in Waist Circumference(Baseline, Week 64)
- Change from Baseline in Hemoglobin A1c (HbA1c)(Baseline, Week 64)
- Percent Change in Baseline in Triglycerides(Baseline, Week 64)
- Change from Baseline in Systolic Blood Pressure(Baseline, Week 64)
- Change from Baseline in Body Mass Index (BMI)(Baseline, Week 64)
- Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP)(Baseline, Week 64)
- Percent Change from Baseline in Fasting Insulin(Baseline, Week 64)
- Change in Medication Use(Baseline through Week 64)
- Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)(Baseline, Week 64)
- Change from Baseline in Short Form-36 (SF-36 v2) Score(Baseline, Week 64)
- Change from Baseline in EQ-5D-5L Score(Baseline, Week 64)
- Change from Baseline in Control of Eating Questionnaire (CoEQ) Score(Baseline, Week 64)
- Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight(Baseline, Week 64)
- Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)(Baseline through Week 64)
- PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)(Baseline through Week 64)
研究者
研究点 (322)
Loading locations...
相似试验
终止
3 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 Diabetes MellitusNCT03496298Sanofi4,076
已完成
2 期
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)Ulcerative ColitisNCT05372939Applied Molecular Transport51
进行中（未招募）
2 期
Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)Ulcerative ColitisNCT04583358Applied Molecular Transport105
进行中（未招募）
2 期
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNCT05297890CStone Pharmaceuticals70
终止
4 期
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive BladderOveractive BladderNCT01302938Pfizer's Upjohn has merged with Mylan to form Viatris Inc.18